Skip to main content
Equibles

UBS Group AG

Position in LLY — ELI LILLY & Co

CIK 1610520 ZURICH, V8
Back to LLY Full portfolio

Position in LLY

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$4,636,914,000
+$917,761,464 QoQ
Shares Held
3,865,931
-4.4% QoQ
Ownership
0.411%
of shares outstanding
% of Portfolio
0.95%
of 13F equity value
Holder Rank
#37
of 4,621 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 21% Shared 0% None 79%

Common Shares in LLY Over Time

Shares Held

Position Value (USD)

Derivatives in LLY

reported options exposure · as of Jun 30, 2026
CallValue
$8,756,297,912
CallShares
7,300,382
PutValue
$454,344,121
PutShares
378,800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

UBS Group AG holds $17,056,271,930 across 20 Drug Manufacturers - General names. LLY ranks #1 (27.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
This page 		3,865,931 $4,636,914,000
2 ABBV
AbbVie Inc.
 12,845,120 $3,232,345,993
3 JNJ
Johnson & Johnson
 11,036,891 $2,803,039,201
4 MRK
Merck & Co., Inc.
 13,744,783 $1,766,204,613
5 AMGN
Amgen Inc
 3,308,695 $1,198,144,628
6 AZN
Astrazeneca PLC
 5,297,462 $1,004,504,738
7 GILD
Gilead Sciences, Inc.
 4,503,294 $568,946,162
8 BMY
Bristol Myers Squibb Co
 8,876,439 $511,460,413

All Filings in LLY

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $454,344,121 378,800
2026-06-30 $8,756,297,912 7,300,382
2026-06-30 $4,636,914,000 3,865,931
2026-03-31 $143,749,013 156,288
2026-03-31 $364,320,897 396,100
2026-03-31 $3,719,152,536 4,043,568
2025-12-31 $3,830,073,896 3,563,920
2025-12-31 $256,994,700 239,136
2025-12-31 $357,636,342 332,784
2025-09-30 $3,029,296,935 3,970,245
2025-09-30 $300,922,622 394,394
2025-09-30 $217,851,760 285,520
2025-06-30 $162,850,832 208,909
2025-06-30 $311,601,526 399,730
2025-06-30 $3,055,295,333 3,919,407
2025-03-31 $136,608,817 165,404
2025-03-31 $375,541,277 454,700
2025-03-31 $3,170,546,249 3,838,852
2024-12-31 $190,143,600 246,300
2024-12-31 $130,000,168 168,394
2024-12-31 $2,625,679,308 3,401,139
2024-09-30 $164,956,712 186,194
2024-09-30 $247,443,042 279,300
2024-09-30 $3,185,768,471 3,595,919
2024-06-30 $129,065,540 142,554
2024-06-30 $2,682,478,868 2,962,821
2024-06-30 $167,042,610 184,500
2024-03-31 $2,092,109,477 2,689,225
2024-03-31 $129,841,524 166,900
2024-03-31 $164,305,152 211,200
2023-12-31 $126,488,976 216,992
2023-12-31 $1,482,936,233 2,543,979
2023-12-31 $154,696,475 265,382
2023-09-30 $1,194,051,265 2,223,021
2023-09-30 $42,057,279 78,300
2023-09-30 $58,154,527 108,269
2023-06-30 $19,462,670 41,500
2023-06-30 $1,144,523,644 2,440,453
2023-06-30 $26,591,166 56,700
2023-03-31 $12,740,882 37,100
2023-03-31 $800,483,511 2,330,917
2023-03-31 $17,926,524 52,200
2022-12-31 $16,353,048 44,700
2022-12-31 $24,989,432 68,307
2022-12-31 $697,983,205 1,907,892
2022-09-30 $10,023,850 31,000
2022-09-30 $1,616,750 5,000
2022-09-30 $340,187,799 1,052,073
2022-06-30 $8,429,980 26,000
2022-06-30 $384,824,044 1,186,886

Report a Problem

Category
Description
Email (optional, for follow-up)